ZYUS Life Sciences (TSXV:ZYUS) EPS (Basic): C$-0.27 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:ZYUS ZYUS Life Sciences Corp TSXV:ZYUS
16 GF Score
Price C$0.50
! 6 Warning Signs
View Full Analysis

What is ZYUS Life Sciences EPS (Basic)?

ZYUS Life Sciences TSXV:ZYUS 16 EPS (Basic) is C$-0.27 as of Mar. 2026. GuruFocus rates TSXV:ZYUS with a GF Score™ of 16/100. The stock has 6 warning signs investors should review.

ZYUS Life Sciences's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was C$-0.04. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was C$-0.27.

ZYUS Life Sciences's EPS (Diluted) for the three months ended in Mar. 2026 was C$-0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was C$-0.27.

ZYUS Life Sciences's EPS without NRI for the three months ended in Mar. 2026 was C$-0.04. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.21.

During the past 3 years, the average EPS without NRI Growth Rate was 16.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, ZYUS Life Sciences's highest 3-Year average EPS without NRI Growth Rate was 16.60% per year. The lowest was 16.60% per year. And the median was 16.60% per year.


ZYUS Life Sciences  (TSXV:ZYUS) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


ZYUS Life Sciences EPS (Basic) Related Terms


ZYUS Life Sciences EPS (Basic) Historical Data

* Premium members only.

The historical data trend for ZYUS Life Sciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZYUS Life Sciences EPS (Basic) Chart

ZYUS Life Sciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
-0.34 -0.35 -0.76 -0.47 -0.28

ZYUS Life Sciences Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.06 -0.05 -0.12 -0.04
TSXV:ZYUS
16GF Score
ZYUS Life Sciences Corp TSXV:ZYUS
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ZYUS Life Sciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

ZYUS Life Sciences's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-21.731-0)/76.812
=-0.28

ZYUS Life Sciences's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-3.062-0)/80.127
=-0.04

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of C$-0.27 mean?
ZYUS Life Sciences (TSXV:ZYUS) has a EPS (Basic) of C$-0.27 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on ZYUS Life Sciences and its competitors.
Is ZYUS Life Sciences' EPS (Basic) too high?
ZYUS Life Sciences' current EPS (Basic) is C$-0.27. Overall, ZYUS Life Sciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does ZYUS Life Sciences' EPS (Basic) compare to ZTS and UTHR?
ZYUS Life Sciences' EPS (Basic) of C$-0.27 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on ZYUS Life Sciences and its competitors. ZYUS Life Sciences's current EPS (Basic) is C$-0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
ZYUS Life Sciences (TSXV:ZYUS) has a current EPS (Basic) of C$-0.27. The current EPS (Basic) is C$-0.27. ZYUS Life Sciences' overall GF Score™ is 16/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For ZYUS Life Sciences (TSXV:ZYUS), the current EPS (Basic) is C$-0.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ZYUS Life Sciences Business Description

Other Exchanges ZLSCF:USA
Address 407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
16GF Score

Get the complete analysis for TSXV:ZYUS

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.50
Price